The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Severe Hypoglycemia and Risks of Vascular Events and Death
Open accessAbstract
BACKGROUND: Severe hypoglycemia may increase the risk of a poor outcome in patients with type 2 diabetes assigned to an intensive glucose-lowering intervention. We analyzed data from a large study of intensive glucose lowering to explore the relationship between severe hypoglycemia and adverse clinical outcomes. METHODS: We examined the associations between severe hypoglycemia and the risks of macrovascular or microvascular events and death among 11,140 patients with type 2 diabetes, using Cox proportional-hazards models with adjustment for covariates measured at baseline and after randomization. RESULTS: During a median follow-up period of 5 years, 231 patients (2.1%) had at least one severe hypoglycemic episode; 150 had been assigned to intensive glucose control (2.7% of the 5571 patients in that group), and 81 had been assigned to standard glucose control (1.5% of the 5569 patients in that group). The median times from the onset of severe hypoglycemia to the first major macrovascular event, the first major microvascular event, and death were 1.56 years (interquartile range, 0.84 to 2.41), 0.99 years (interquartile range, 0.40 to 2.17), and 1.05 years (interquartile range, 0.34 to 2.41), respectively. During follow-up, severe hypoglycemia was associated with a significant increase in the adjusted risks of major macrovascular events (hazard ratio, 2.88; 95% confidence interval [CI], 2.01 to 4.12), major microvascular events (hazard ratio, 1.81; 95% CI, 1.19 to 2.74), death from a cardiovascular cause (hazard ratio, 2.68; 95% CI, 1.72 to 4.19), and death from any cause (hazard ratio, 2.69; 95% CI, 1.97 to 3.67) (P<0.001 for all comparisons). Similar associations were apparent for a range of nonvascular outcomes, including respiratory, digestive, and skin conditions (P<0.01 for all comparisons). No relationship was found between repeated episodes of severe hypoglycemia and vascular outcomes or death. CONCLUSIONS: Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes. It is possible that severe hypoglycemia contributes to adverse outcomes, but these analyses indicate that hypoglycemia is just as likely to be a marker of vulnerability to such events. (Funded by Servier and the National Health and Medical Research Council of Australia; ClinicalTrials.gov number, NCT00145925.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the frequency of severe hypoglycemia in these trials was 2 to 3 times higher in the intensive therapy groups”
From Targets for Glycemic Control (2018) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with type 2 diabetes and established, or very high risk for, cardiovascular disease (CVD), there is a clear association between an increased mortality and severe hypoglycemia (62,63) and symptomatic hypoglycemia (64).”
From Hypoglycemia (2018) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Post hoc analysis of clinical trials examining the effects of strict glycemic control on cardiovascular outcomes showed that exposure to severe hypoglycemia was strongly associated with a range of adverse outcomes, including death (2, 3).”
From Effect of Hypoglycemia on QT Interval in Individuals With and Without Type 2 Diabetes: A Randomized Crossover Trial (2025) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“In ADVANCE, where rates of hypoglycemia were low, a similar pattern was found (47).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [47]
The cited source says what the claim attributes to it.
In the citing paper
“a higher mortality was reported in participants with 1 or more episodes of severe hypoglycemia in the ACCORD (30), ADVANCE (31) and VADT trials (25), irrespective of the different treatment arms in which individual participants were allocated.”
From Targets for Glycemic Control (2018) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“An association of level 3 hypoglycemia with mortality was also found in the ADVANCE trial and in clinical practice (77,78).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [77]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“U500 regular insulin (contains 500 units/mL of regular insulin) may improve glycemia in the therapy of persons with DM who have severe insulin resistance (eg, require >200 total units of insulin/day).1102–1105”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1105]
Experimental — accuracy not yet measuredIn the citing paper
“multiple studies have shown a strong relationship between hypoglycemia (severe or not severe) and cardiovascular events and mortality”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [197]
In the citing paper
“All three trials clearly demonstrated that an episode of severe hypoglycemia was associated with an increased risk of subsequent mortality.”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [47]
In the citing paper
“In ADVANCE, where rates of hypoglycemia were low, a similar pattern was found (47).”
From Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society (2013) · cites this paper as [47]
In the citing paper
“An association of level 3 hypoglycemia with mortality was also found in the ADVANCE trial (90).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Rovere, M. T. L., Bigger, J. T., Marcus, F. I., Mortara, A., & Schwartz, P. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11144-8 · Cited by 3,120
Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054
Self-citationIntensive glucose control and macrovascular outcomes in type 2 diabetes
Turnbull, F. M., Abraira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1470-0 · Cited by 1,189
Self-citationGerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Bonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Flagged first, then by citations
Research works printed but not linked: 3
- Therneau TM, Grambsch PM. Modelling survival data: extending the Cox model. New York: Springer, 2000.
- Hoekstra JBL, 2009, Diabetologia, 52, 237
- Miller ME, 2009, Diabetologia, 52, 63
Cited by
Sorted by citations
Items 801–900 of 1,002
Davis, W. A., Brown, S. G. A., Jacobs, I. G., Bulsara, M. K., Beilby, J. P., Bruce, D. G., & Davis, T. M. E. (2011) · Endocrinology · doi:10.1210/endo.152.3.zee1195a · Cited by 11
All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
Strandberg, A. Y., Hoti, F. J., Strandberg, T. E., Christopher, S., Haukka, J. K., & Korhonen, P. A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151910 · Cited by 11
Tanaka, S., Kawasaki, R., Tanaka‐Mizuno, S., Iimuro, S., Matsunaga, S., Moriya, T., Ishibashi, S., Katayama, S., Ohashi, Y., Akanuma, Y., et al. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.06.002 · Cited by 11
Kadowaki, T., Haneda, M., Ito, H., Sasaki, K., & Yamada, Y. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01306-0 · Cited by 11
Kawaguchi, Y., Sawa, J., Hamai, C., Nishimura, Y., & Kumeda, Y. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.13038 · Cited by 10
Villani, M., Earnest, A., Smith, K. L., de Courten, B. V., & Zoungas, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-23457-5 · Cited by 10
Self-citationAllamreddy, S. R., Arora, M., Ganugula, R., Friend, R., Basu, R., & Kumar, M. N. V. R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001074 · Cited by 10
Diabetes and sudden cardiac death: a Danish nationwide study
Skjelbred, T., Warming, P. E., Behr, E. R., Køber, L., Pedersen‐Bjergaard, U., Winkel, B. G., Lynge, T. H., & Tfelt‐Hansen, J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf826 · Cited by 11
Wang, C., Lin, C., Huang, T.-S., Chien, M.-N., Hsieh, S., Huang, Y., Shih, K., Tu, S., Chang, C., Huang, C., et al. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.017 · Cited by 10
Gallwitz, B., Rosenstock, J., Patel, S., von Eynatten, M., Hehnke, U., MEHLBURGER, L., Dugi, K. A., & Woerle, H. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12419 · Cited by 10
Kuo, S., Yang, C., Wu, J., & Ou, H. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13525 · Cited by 10
Wang, J., Lo, S., Yeh, Y., Hwu, C., Huang, C., Hsieh, C., & Sheu, W. H. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14410 · Cited by 10
Westall, S., Narayanan, R. P., Watmough, S., Irving, G. J., Furlong, N. J., McNulty, S., Bujawansa, S., & Hardy, K. J. (2022) · Clinical Medicine · doi:10.7861/clinmed.2021-0764 · Cited by 12
Pilla, S. J., Jalalzai, R., Tang, O., Schoenborn, N. L., Boyd, C. M., Bancks, M. P., Mathioudakis, N. N., & Maruthur, N. M. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08506-8 · Cited by 10
Bron, M., Wilson, C., & Fleck, P. R. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0088-5 · Cited by 10
Motherhood, Apple Pie, Hemoglobin A1C, and the DCCT
Trence, D., & Hirsch, I. B. (2012) · Endocrine Practice · doi:10.4158/ep11359.ra · Cited by 10
Hoogwerf, B. J., Lincoff, A. M., Rodríguez, Á., Chen, L., & Qu, Y. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0393-6 · Cited by 10
Blood glucose monitoring in type 2 diabetes – Nepalese patients’ opinions and experiences
Sapkota, S., Brien, J.-A. E., & Aslani, P. (2017) · Global Health Action · doi:10.1080/16549716.2017.1322400 · Cited by 10
Kern, W., Holstein, A., Moenninghoff, C., Kienhöfer, J., Riedl, M., & Kulzer, B. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-112350 · Cited by 10
Fujimoto, K., Shibayama, Y., Yamaguchi, E., Honjo, S., Hamasaki, A., & Hamamoto, Y. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12658 · Cited by 10
Soltani, G., Hatefi, Z., Salehi, A. R., Khosravi, S., Ghiasi, M. R., Teke, K., Aminorroaya, A., & Salehi, R. (2018) · Advanced Biomedical Research · doi:10.4103/abr.abr_144_17 · Cited by 10
Reiff, S., & Fava, S. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.10.014 · Cited by 10
Mylona, M., Liatis, S., Anastasiadis, G., Kapelios, C. J., & Kokkinos, A. D. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108038 · Cited by 10
Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom
Gordon, J. P., Evans, M., McEwan, P. C., Bain, S. C., & Vora, J. P. (2013) · Diabetes Therapy · doi:10.1007/s13300-012-0018-3 · Cited by 10
Inzucchi, S. E., & Sherwin, R. S. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00237-2 · Cited by 10
Amod, A., Buse, J. B., McGuire, D. K., Pieber, T. R., Pop‐Busui, R., Pratley, R. E., Zinman, B., Hansen, M. B., Jia, T., Mark, T., et al. (2020) · Diabetes and Vascular Disease Research · doi:10.1177/1479164120970933 · Cited by 10
Pasciak, W., Berg, D. N., Cherlin, E. J., Fried, T. R., & Lipska, K. J. (2021) · BMC Geriatrics · doi:10.1186/s12877-021-02268-w · Cited by 10
Uanini, N. (2001) · Dialnet (Universidad de la Rioja) · Cited by 10
Predictors of hypoglycemia in insulin-treated patients with type 2 diabetes mellitus in Basrah
Nassar, D. T., Habib, O. S., & Mansour, A. A. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i18.470 · Cited by 10
Kataoka, Y., Kitahara, S., Funabashi, S., Makino, H., Matsubara, M., Matsuo, M., Omura‐Ohata, Y., Koezuka, R., Tochiya, M., Tamanaha, T., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108592 · Cited by 9
Chiang, C., Wang, K.-L., Cheng, H., Chao, T., & Sung, S. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001263 · Cited by 9
Preventing hypoglycaemia: an elusive quest
Sinclair, A. J., & Bellary, S. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30109-7 · Cited by 9
Dalem, J. D. R.-V., Brouwers, M. C. G. J., Stehouwer, C. D. A., Krings, A., Klungel, O. H., Driessen, J. H. M., de Vries, F., & Burden, A. M. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13168 · Cited by 9
Kimura, Y., Kimura, N., & Akazawa, M. (2021) · Diabetology International · doi:10.1007/s13340-021-00499-1 · Cited by 9
Ri, M., Nunobe, S., Ida, S., Ishizuka, N., Atsumi, S., Hayami, M., Makuuchi, R., Kumagai, K., Ohashi, M., & Sano, T. (2021) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2021.21.e31 · Cited by 9
Sanz, J., & Fuster, V. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.03.052 · Cited by 9
Algendy, A. F., Illigens, B. M. W., & Alyazeedi, A. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s339331 · Cited by 9
Lavikainen, P., Chandra, G., Siirtola, P., Tamminen, S., Ihalapathirana, A., Röning, J., Laatikainen, T. K., & Martikainen, J. A. (2023) · Clinical Epidemiology · doi:10.2147/clep.s380828 · Cited by 10
Effect of Cardiac Resynchronization Therapy in Patients With Insulin-Treated Diabetes Mellitus
Szepietowska, B., Kutyifa, V., Ruwald, M. H., Solomon, S. D., Ruwald, A., McNitt, S. A., Polonsky, B., Thomas, S., Moss, A. J., & Zaręba, W. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.04.053 · Cited by 9
Patient Factors Associated with Glucagonlike Peptide 1 Receptor Agonist use with and without Insulin
Hirsch, I. B., Xu, Y., Davis, K. L., & Calingaert, B. (2011) · Endocrine Practice · doi:10.4158/ep11014.or · Cited by 9
Cardiovascular Effects of Incretin Therapy in Diabetes Care
Kim, J., & Samson, S. L. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0035 · Cited by 9
Fujibayashi, K., Hayashi, M., Yokokawa, H., & Naito, T. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0187-8 · Cited by 9
Kalkan, A., Bodegård, J., Sundström, J., Svennblad, B., Östgren, C. J., Nilsson, P. N., Johansson, G., & Ekman, M. (2016) · Primary care diabetes · doi:10.1016/j.pcd.2016.11.002 · Cited by 9
Hypoglycaemia in patients with diabetes mellitus and renal impairment
Hettige, T., & Cooper, M. E. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164116683082 · Cited by 9
Wako, A., Belay, S., Feleke, Y., & Kebede, T. (2017) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000741 · Cited by 9
Cardiovascular Disease in Japanese Patients with Type 2 Diabetes Mellitus
Fujihara, K., & Sone, H. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.ra.17-00109 · Cited by 9
Iloh, G. U. P., & Amadi, A. (2018) · Journal of Health Research and Reviews · doi:10.4103/jhrr.jhrr_37_17 · Cited by 9
Can hypoglycemic episodes in type 1 diabetics trigger cardiac arrhythmias?
Lainetti, K. R., Pimenta, J., & Vendramini, M. F. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107878 · Cited by 9
Johansen, P., Sandberg, A., & Capehorn, M. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01242-z · Cited by 10
Muller, N., Lehmann, T., Klöss, A., Günster, C., Kloos, C., & Müller, U. (2020) · Diabetic Medicine · doi:10.1111/dme.14294 · Cited by 9
Guo, W., Wang, Q., Pan, S., Li, J., Wang, Y., Shu, Y.-H., Chen, J., Wang, Q., Zhang, S., Zhang, X., et al. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30354 · Cited by 9
Handa, T., Nakamura, A., Miya, A., Nomoto, H., Kameda, H., Cho, K. Y., Nagai, S., Yoshioka, N., Miyoshi, H., & Atsumi, T. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00656-1 · Cited by 9
Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype
Dujić, T., Cvijić, S., Elezović, A., Bego, T., Imamović, S., Malenica, M., Elezović, A., Pearson, E. R., & Kulo, A. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050367 · Cited by 9
Epidemiology of hypoglycaemic episodes leading to hospitalisations in Denmark in 1998–2018
Jensen, M. H., Hejlesen, O. K., & Vestergaard, P. (2021) · Diabetologia · doi:10.1007/s00125-021-05507-2 · Cited by 9
Hypoglykämien und zentrales Nervensystem
Erbguth, F. J. (2013) · Der Diabetologe · doi:10.1007/s11428-012-0911-4 · Cited by 9
Effects of glucose and blood pressure reduction on subclinical cardiac damage: Results from ADVANCE
Juraschek, S. P., Wang, D., McEvoy, J. W., Harrap, S. B., Harris, K., Mancia, G., Marre, M., Neal, B. C., Patel, A. A., Poulter, N. R., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.04.044 · Cited by 9
Self-citationPaul, S. K., Maggs, D. G., Klein, K., & Best, J. H. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12208 · Cited by 9
Optimal utilisation of sulphonylureas in resource-constrained settings : review article
Naidoo, P., Rambiritch, V., Butkow, N., & Saman, S. (2014) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2014-007 · Cited by 9
Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
Åhrén, B. (2013) · European Diabetes Nursing · doi:10.1002/edn.221 · Cited by 9
Kang, D. O., Seo, H. S., Choi, B. G., Lee, E. M., Kim, J. P., Lee, S. K., Im, S. I., Na, J. O., Choi, C. U., Lim, H. E., et al. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.10.164 · Cited by 9
Sulfonylurea monotherapy and emergency room utilization among elderly patients with type 2 diabetes
Rajpathak, S. N., Fu, C., Brodovicz, K., Engel, S. S., & Heaton, P. C. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.05.046 · Cited by 9
Wu, W., Sun, Z., Li, Q., Wang, M., Miao, J., Zheng, Z., Sun, L., Huang, J., Wang, Y., Zhang, H., et al. (2012) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.02.010 · Cited by 9
Self-citationBirkhead, J. S., Weston, C. F. M., Timmis, A., & Chen, R. (2014) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872614549733 · Cited by 9
Lagi, A., Cencetti, S., & Lagi, F. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12426 · Cited by 9
Mitsuishi, S., Nishimura, R., Ando, K., Tsujino, D., & Utsunomiya, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144041 · Cited by 9
Currie, C. J., Holden, S. E., Jenkins‐Jones, S., Morgan, C. L., Voss, B., Rajpathak, S. N., Alemayehu, B., Peters, J. R., & Engel, S. S. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13155 · Cited by 9
Wan, E. Y. F., Yu, E. Y. T., Fung, C. S. C., Chin, W., Fong, D., Chan, A. K. C., & Lam, C. L. K. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.01.012 · Cited by 9
Majumder, A., RoyChaudhuri, S., & Sanyal, D. (2019) · Cureus · doi:10.7759/cureus.6191 · Cited by 9
Múñoz, Ó., Gómez, A. M., Maira, G., Vargas, F. M. L., & Ruiz, Á. J. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.028 · Cited by 9
Mortality, Cardiovascular Morbidity and Possible Effects of Hypoglycaemia on Diabetic Complications
Chow, E., Fisher, M., & Heller, S. R. (2013) · Wiley eBooks · doi:10.1002/9781118695432.ch13 · Cited by 9
Self-citationEditorial: Rethinking the Definition of Diabetes for Precision Medicine
Ahima, R. S. (2015) · Molecular Endocrinology · doi:10.1210/me.2015-1037 · Cited by 9
Makam, S., Stein, L. K., & Dhamoon, M. S. (2024) · Stroke · doi:10.1161/strokeaha.124.049178 · Cited by 8
Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk
Gilliam, L. K., Parker, M. M., Chen, M., Karter, A. J., & GRANT, R. W. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.59946 · Cited by 8
Blood Sugar Targets in Surgical Intensive Care
Roth, J., Sommerfeld, O., Birkenfeld, A. L., Sponholz, C., Müller, U., & von Loeffelholz, C. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0221 · Cited by 10
MicroRNA Changes Up to 24 h following Induced Hypoglycemia in Type 2 Diabetes
Ramanjaneya, M., Bettahi, I., Pawar, K., Halabi, N. M., Moin, A. S. M., Sathyapalan, T., Abou‐Samra, A., Atkin, S. L., & Butler, A. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314696 · Cited by 9
Mellor, J., Kuznetsov, D., Heller, S. R., Gall, M.-A., Rosilio, M., Amiel, S. A., Ibberson, M. R., McGurnaghan, S. J., Blackbourn, L. A. K., Berthon, W., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06177-6 · Cited by 8
Self-citationTseng, Y., Tsan, Y., & Chen, P. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14364 · Cited by 8
Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes
Li, Y., Mu, Y., Ji, Q., Huang, Q., Kuang, H., Ji, L., & Yang, X. (2015) · BioMed Research International · doi:10.1155/2015/862896 · Cited by 8
Martorella, A. J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2299 · Cited by 8
van der Leeuw, J., Visseren, F. L. J., Woodward, M., van der Graaf, Y., Grobbee, D. E., Harrap, S. B., Heller, S. R., Mancia, G., Marre, M., Poulter, N. R., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4082-5 · Cited by 8
Self-citationMuller, N., Lehmann, T. N., Gerste, B., Adler, J., Kloos, C., Hartmann, M., Kramer, G., Kuniß, N., & Müller, U. (2017) · Diabetic Medicine · doi:10.1111/dme.13397 · Cited by 8
Karamat, M. A., Dar, S., Bellary, S., & Tahrani, A. A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0400-x · Cited by 8
Krajnc, M., Balon, B. P., & Krajnc, I. (2019) · Journal of International Medical Research · doi:10.1177/0300060518814080 · Cited by 8
Argente, M., Martínez-Millana, A., Espí-Reig, J., Maupoey, J., Moya‐Herraiz, Á., Castelló, I. B., López‐Andújar, R., & Merino-Torres, J. F. (2021) · Cirugía Española (English Edition) · doi:10.1016/j.cireng.2021.10.001 · Cited by 8
Li-jing, W., Ke, S., Wang, L., Lishan, H., Liqin, Q., Zhan, Z., Kejun, W., Mengjun, Z., Xiaoying, L., Xiaohong, L., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.843556 · Cited by 8
Koufakis, T., Zografou, I., Doumas, M. N., & Kotsa, K. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00610-8 · Cited by 9
Shahreyar, M., Muppidi, V., Choudhuri, I., Sra, J. S., Tajik, A. J., & Jahangir, A. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1059276 · Cited by 8
Body Mass Index–Mortality Relationship in Severe Hypoglycemic Patients With Type 2 Diabetes
Tsai, T.-C., Lee, C., Cheng, B., Kung, C., Chen, F.-C., Shen, F., Lee, C.-J., & Chen, Y.-C. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000382 · Cited by 8
Parsaik, A. K., Carter, R. E., Myers, L. A., Geske, J. R., Smith, S. A., Levine, J. A., Basu, A., & Kudva, Y. C. (2012) · Endocrine Practice · doi:10.4158/ep12094.or · Cited by 8
Cardiovascular Importance of Hyperglycemia and Hypoglycemia
Tkáč, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2044 · Cited by 8
Dąbek, J., Bałys, M., Majewski, M., & Gąsior, Z. (2016) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/58785 · Cited by 8
Blood pressure management in patients with type 2 diabetes mellitus
Kai, H. (2017) · Hypertension Research · doi:10.1038/hr.2017.55 · Cited by 8
Anfinogenova, Y., Grakova, E. V., Shvedova, M., Kopeva, K. V., Teplyakov, A. T., & Popov, S. V. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9647-y · Cited by 8
Haluzı́k, M., Kretowski, A. J., Strojek, K., Czupryniak, L., Janež, A., Kempler, P., Anděl, M., Tankova, T. I., Boyanov, M., Duvnjak, L. S., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0388-2 · Cited by 8
The Intersection of Diabetes and Cardiovascular Disease—A Focus on New Therapies
Dhindsa, D. S., Sandesara, P. B., & Shapiro, M. D. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00160 · Cited by 9
Wang, J., Chen, H., Tang, F., & Sheu, W. H. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13485 · Cited by 8
Ettori-Ajasse, I., Tatin, E., Forbes, G., Eldridge, S. M., & Dibao-Dina, C. (2020) · Trials · doi:10.1186/s13063-020-4215-5 · Cited by 9
Is it time to ban sulfonylureas?
Ceriello, A. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13095 · Cited by 8
Ruiz-Aranda, D., Mateo‐Rodríguez, C., Olmedo, I. S., García, C. G., Enríquez, A. J., & Martínez‐Brocca, M. A. (2020) · Sustainability · doi:10.3390/su12208512 · Cited by 8
Komorita, Y., Minami, M., Maeda, Y., Yoshioka, R., Ohkuma, T., & Kitazono, T. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002099 · Cited by 8
Metadata
- Authors
- Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., Grobbee, D. E., Kengne, A. P., Marre, M., & Heller, S.
- Affiliations
- The University of Sydney (AU)
- University Medical Center Utrecht (NL)
- Hôpital Bichat-Claude-Bernard (FR)
- National Health Service (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-10-07
- Volume
- 363
- Issue
- 15
- Pages
- 1410-1418
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2097995302
- Semantic Scholar
- b73e51368b0f6c3d0c425e6670188db927bc8b09
- Cited by
- 1,471
- References
- 31
- Citations by year
- 2026: 33 · 2025: 49 · 2024: 64 · 2023: 60 · 2022: 66 · 2021: 103 · 2020: 119 · 2019: 99 · 2018: 113 · 2017: 103 · 2016: 107 · 2015: 147 · 2014: 106 · 2013: 98 · 2012: 103
- FWCI
- 71.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- severe hypoglycemia, type 2 diabetes, tight glycemic control, macrovascular events, cardiovascular mortality, all-cause mortality, adverse clinical outcomes, diabetes complications, UKPDS
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Gliclazide, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Risk Factors, Vascular Diseases, Proportional Hazards Models, Microvessels
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
